These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2018 related items for PubMed ID: 11770175

  • 1. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M.
    Orv Hetil; 2001 Nov 18; 142(46):2563-8. PubMed ID: 11770175
    [Abstract] [Full Text] [Related]

  • 2. Antibodies as molecular target-based therapy: trastuzumab.
    Tokuda Y.
    Int J Clin Oncol; 2003 Aug 18; 8(4):224-9. PubMed ID: 12955577
    [Abstract] [Full Text] [Related]

  • 3. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM.
    Clin Ther; 1999 Feb 18; 21(2):309-18. PubMed ID: 10211534
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct 18; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

  • 5. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S.
    Semin Oncol; 1999 Aug 18; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [Abstract] [Full Text] [Related]

  • 6. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P, Guarneri V, Bengala C.
    Clin Breast Cancer; 2007 Dec 18; 7(11):841-9. PubMed ID: 18269773
    [Abstract] [Full Text] [Related]

  • 7. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M, Trastuzumab Response Biomarker Group.
    Cancer; 2010 Nov 15; 116(22):5168-78. PubMed ID: 20661914
    [Abstract] [Full Text] [Related]

  • 8. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
    Breast Cancer Res; 2005 Nov 15; 7(4):R436-43. PubMed ID: 15987448
    [Abstract] [Full Text] [Related]

  • 9. [Breast cancer].
    Tokuda Y, Saito Y, Suzuki Y, Ohta M, Tajima T.
    Nihon Rinsho; 2002 Mar 15; 60(3):563-9. PubMed ID: 11904974
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L.
    Semin Oncol; 1999 Aug 15; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [Abstract] [Full Text] [Related]

  • 11. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
    Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE.
    Clin Breast Cancer; 2005 Aug 15; 6(3):247-52. PubMed ID: 16137436
    [Abstract] [Full Text] [Related]

  • 12. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.
    J Clin Oncol; 2003 Aug 01; 21(15):2889-95. PubMed ID: 12885806
    [Abstract] [Full Text] [Related]

  • 13. [Rationale for Herceptin in the clinical use].
    Ebi H, Sasaki Y.
    Nihon Rinsho; 2002 Mar 01; 60(3):463-7. PubMed ID: 11904959
    [Abstract] [Full Text] [Related]

  • 14. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA.
    Am J Ther; 2005 Mar 01; 12(3):243-53. PubMed ID: 15891269
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.
    J Clin Oncol; 2011 Feb 01; 29(4):398-405. PubMed ID: 21172893
    [Abstract] [Full Text] [Related]

  • 16. Progression and treatment of HER2-positive breast cancer.
    Davoli A, Hocevar BA, Brown TL.
    Cancer Chemother Pharmacol; 2010 Mar 01; 65(4):611-23. PubMed ID: 20087739
    [Abstract] [Full Text] [Related]

  • 17. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M.
    Hematol Oncol Clin North Am; 2007 Apr 01; 21(2):239-56. PubMed ID: 17512447
    [Abstract] [Full Text] [Related]

  • 18. [Herceptin and its therapeutic strategy in patients with breast cancer overexpressing HER2].
    Tajima T, Suzuki Y, Tokuda Y.
    Gan To Kagaku Ryoho; 2002 Jul 01; 29(7):1132-7. PubMed ID: 12145992
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J, Perez EA, Pienkowski T, Bell R.
    Oncologist; 2006 Jul 01; 11 Suppl 1():4-12. PubMed ID: 16971734
    [Abstract] [Full Text] [Related]

  • 20. [Herceptin-based therapy for breast cancer].
    Tokuda Y, Saito Y, Suzuki Y.
    Nihon Rinsho; 2006 Mar 01; 64(3):540-5. PubMed ID: 16529047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 101.